| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 0 | 38.583 | 14.638 | 13.669 | 13.079 |
| Total Income - EUR | - | - | - | - | - | 0 | 38.584 | 14.638 | 13.669 | 13.079 |
| Total Expenses - EUR | - | - | - | - | - | 105 | 8.824 | 2.234 | 2.552 | 2.933 |
| Gross Profit/Loss - EUR | - | - | - | - | - | -105 | 29.760 | 12.404 | 11.117 | 10.146 |
| Net Profit/Loss - EUR | - | - | - | - | - | -105 | 29.246 | 11.987 | 9.281 | 8.446 |
| Employees | - | - | - | - | - | 0 | 1 | 0 | 0 | 0 |
Check the financial reports for the company - Dr. Abu-Alhija Sary S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | - | 48 | 30.685 | 13.380 | 11.594 | 8.908 |
| Inventories | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | 0 | 25.029 | 9.235 | 2.257 | 513 |
| Cash | - | - | - | - | - | 48 | 5.656 | 4.146 | 9.337 | 8.395 |
| Shareholders Funds | - | - | - | - | - | -64 | 29.214 | 12.035 | 9.329 | 8.494 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 112 | 1.471 | 1.345 | 2.265 | 451 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Dr. Abu-Alhija Sary S.r.l.